Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
13 studies found for:    "Myoclonus epilepsy"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Unknown  Physical Exercise in Subjects With Juvenile Myoclonic Epilepsy
Conditions: Epilepsy;   Epilepsia;   Epileptic Seizures;   Seizure Disorder
Intervention: Behavioral: Physical activity
2 Enrolling by invitation Effect of Ropinirole Hydrochloride in Progressive Myoclonic Epilepsy of Unverricht-Lundborg Type
Condition: Unverricht-Lundborg Syndrome
Intervention: Drug: Ropinirole
3 Terminated
Has Results
Efficacy and Safety of Adjunctive Zonisamide in Myoclonic Seizures Associated With Idiopathic Generalised Epilepsy
Condition: Epilepsy
Interventions: Drug: Zonisamide;   Drug: Placebo
4 Completed Effect of Levetiracetam on Brain Excitability
Conditions: Healthy;   Myoclonic Epilepsy
Intervention:
5 Completed Levetiracetam as add-on Treatment of Myoclonic Jerks in Adolescents + Adults
Condition: Generalized Convulsive Epilepsy
Intervention: Drug: Levetiracetam
6 Completed
Has Results
Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease (ULD) in Adolescents and Adults
Condition: Unverricht-Lundborg Disease
Interventions: Other: Placebo;   Drug: BRV 2.5 mg;   Drug: BRV 25 mg;   Drug: BRV 50 mg
7 Completed Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease in Adolescents and Adults
Condition: Unverricht-Lundborg Disease
Interventions: Drug: Brivaracetam 25 mg;   Drug: Brivaracetam 50 mg;   Other: Placebo
8 Completed
Has Results
Open-Label Extension Study to Assess the Safety and Seizure Frequency Associated With Lacosamide for Primary Generalized Tonic-Clonic Seizures in Subjects With Epilepsy
Condition: Epilepsy
Intervention: Drug: Lacosamide
9 Completed
Has Results
Open-Label Study to Assess Lacosamide Safety as Add-on Therapy for Primary Generalized Tonic-Clonic Seizures in Subjects With Epilepsy
Condition: Epilepsy
Intervention: Drug: Lacosamide
10 Recruiting Genetic Characterization of Movement Disorders and Dementias
Conditions: Ataxia;   Dystonia;   Parkinson's Disease;   Amyotrophic Lateral Sclerosis;   Corticobasal Degeneration;   Multiple System Atrophy;   Alzheimer's Disease;   Lewy Body Dementia;   Parkinson Disease-Dementia;   Dentatorubral-pallidoluysian Atrophy;   Creutzfeldt-Jakob Disease and Fatal Familial Insomnia;   Fragile X-associated Tremor/Ataxia Syndrome;   Krabbe's Disease;   Niemann-Pick Disease, Type C;   Neuronal Ceroid Lipofuscinosis
Intervention:
11 Completed Ketogenic Diet in Lafora Disease
Condition: Lafora Disease
Intervention:
12 Completed Clinical and Genetic Studies of Familial Presenile Dementia With Neuronal Inclusion Bodies
Conditions: Familial Dementia With Neuroserpin Inclusion Bodies;   Nervous System Heredodegenerative Disorder
Intervention:
13 Enrolling by invitation Open-Label, Dose-Escalating Study to Assess Safety, Tolerability, Efficacy, PK and PD of RP103 in Children With Inherited Mitochondrial Disease
Condition: Inherited Mitochondrial Disease, Including Leigh Syndrome
Intervention: Drug: Cysteamine Bitartrate Delayed-release Capsules (RP103)

Study has passed its completion date and status has not been verified in more than two years.